Saint Luke's Health System

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Saint Luke's Health System sits in the top decile of US sponsors by registered trial count (#604 of 15,742 sponsors by registered trial count).

26 total trials 2 currently recruiting 18 completed later-stage tilt top decile by trial count

Saint Luke's Health System: 26 sponsored US clinical trials, 2 recruiting.

Saint Luke's Health System sponsors 26 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 18 completed. 5 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Chronic Heart Failure With Preserved Systolic Function, with 1 trials.

Top-decile sponsor footprint

Saint Luke's Health System ranks in the top decile of sponsors by registered trial count (#604 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 35/100

18 of 23 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

26 total, page 1 of 1

RECRUITING NA

Quantification of Debris Captured Using TCEP During VIV TAVR With BVF

NCT05093764

RECRUITING NA

Effect of a Quality Improvement Initiative to Address Social Determinants of Health on Rehospitalization Rates in Patients With Heart Failure

NCT05388097

ACTIVE NOT RECRUITING

The Heart Outcomes in Pregnancy Expectations (H.O.P.E) Registry

NCT04828070

COMPLETED NA

STAR and Deferred Stenting Study

NCT05089864

COMPLETED

Implementation of CareCube Negative Pressure Isolation Units

NCT05229926

COMPLETED Phase 3

Dapagliflozin in Respiratory Failure in Patients With COVID-19

NCT04350593

COMPLETED

SCOPE CLI (Shifting Care and Outcomes for Patients With Endangered Limbs - Critical Limb Ischemia)

NCT03171259

TERMINATED

NICOM in Pregnant Women With Heart Disease

NCT03616730

TERMINATED

Release of Acetylcholine From the Ganglionated Plexus During the Thaw Phase of Cryoballon Pulmonary Vein Ablation (GP RESPONSE Study)

NCT03636100

TERMINATED NA

Initial Management of Patients Receiving a Single Shock (IMPRESS)

NCT03531502

COMPLETED

VAscular Closure for Cardiac Ablation Registry (VACCAR)

NCT03546439

COMPLETED NA

Better Outcomes for Anticoagulation Treatment Through Observation of Atrial Rhythm

NCT03515083

COMPLETED Phase 4

Empagliflozin Impact on Hemodynamics in Patients With Heart Failure

NCT03030222

COMPLETED NA

SHOWME-PAD (Peripheral Artery Disease)

NCT03190382

COMPLETED Phase 4

Dapagliflozin in PRESERVED Ejection Fraction Heart Failure

NCT03030235

COMPLETED

Outcomes of Surgically Ineligible Patients With Multivessel CAD

NCT02996877

COMPLETED Phase 4

Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure

NCT02653482

COMPLETED NA

One More Magnetic Resonance Imaging

NCT02293070

COMPLETED

Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion

NCT02026466

COMPLETED

Patient-centered Outcomes Related to TReatment Practices in Peripheral Arterial Disease: Investigating Trajectories (PORTRAIT)

NCT01419080

COMPLETED

Angina Prevalence and Provider Evaluation of Angina Relief

NCT01705054

TERMINATED

Comparison of Different Locations for Pulse Oximetry Probes in Cardiovascular (CV) Patients With Poor Peripheral Perfusion

NCT01128036

TERMINATED NA

Single-Incision Laparoscopic Cholecystectomy Versus Traditional Laparoscopic Cholecystectomy

NCT01195285

COMPLETED

Transforming PCI Informed Consent Into an Evidence-based Decision-making Tool

NCT01383382

COMPLETED Phase 4

Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients

NCT00736229

COMPLETED

Diabetes Genome Project: A Prospective Registry to Identify Genetic Variation Among Diabetic Patients

NCT00428961

Where Saint Luke's Health System enrollment is open (later-stage tilt)

2 recruiting of 26 indexed (8% open); 18 completed (69%).

Phase mix: 5 late (III/IV) vs 0 early (I/II) (later-stage heavy).

Top condition: Chronic Heart Failure With Preserved Systolic Function (1 trial), 6 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Saint Luke's Health System: open-pipeline peers nationwide

Peers matched on 26 registered trials and 8% open enrollment, not the therapeutic-area sidebar.

Saint Luke's Health System sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1015202530 0%5%10%15%20% Total trials Recruiting share Saint Luke's Health SystemAbbott Diabetes CareAldeyra TherapeuticsCalifornia Polytechnic State University-San Luis ObispoDexComAlumisAndrei IagaruBioXcel TherapeuticsCorporal Michael J. Crescenz VA Medical Center
Saint Luke's Health System sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Saint Luke's Health System sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 26 trials (± recruiting share)

Sponsors near 8% open enrollment (± trial volume)

What to do with this Saint Luke's Health System page

26 registered trials is a research-attention snapshot, not an endorsement of Saint Luke's Health System or any single study.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Saint Luke's Health System pipeline card: 26 registered trials from official public datasets.Report a data error.